An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.

ABSTRACT: Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small molecule therapies. This can restrict patient access and treatment length leading to suboptimal clinical outcomes. Several biosimilar candidates of ranibizumab and aflibercept are currently in development and the first biosimilar of ranibizumab received EMA approval in August and FDA approval in September 2021. Biosimilars are biological medicines that are highly similar to an already-approved biological medicine (reference product). The physicochemical and clinical similarity of a biosimilar is determined by a rigorous analytical and clinical program, including extensive p

SUBMITTER: Hariprasad SM 

PROVIDER: S-EPMC9114261 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature